365-60-6

Upstream product

• 98-16-8 3-trifluoromethylaniline 
• 98-95-3 nitrobenzene 
• 1493-27-2 ortho-nitrofluorobenzene 

Downstream Products

• 43034-86-2 N¹-(3-(trifluoromethyl)phenyl)benzene-1,2-diamine 
• 83657-11-8 Ethoxycarbonyl-3, hydroxy-1 ((trifluoromethyl-3 phenylamino)-2) phenyl-1 uree 

Relevant academic research and scientific papers

TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF

Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, compositions, and mixtures thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing diseases (e.g., proliferative diseases (e.g., cancers, such as carcinoma, sarcoma, lung cancer, thyroid cancer, skin cancer, ovarian cancer, colorectal cancer, prostate cancer, pancreatic cancer, esophageal cancer, liver cancer, breast cancer)) in a subject. Provided are methods of inhibiting a TEAD transcription factors (e.g., TEAD1, TEAD2, TEAD3, TEAD4) in a subject.

Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B

The hepatitis C virus (HCV) NS5B polymerase is an attractive target for the development of novel and selective inhibitors of HCV replication. In this paper, the design, synthesis, and preliminary SAR studies of novel inhibitors of HCV NS5B polymerase based on the structure of tegobuvir have been described. The efforts to optimize the antiviral potency and reduce the treatment side effects with respect to genotype 1b resulted in the discovery of compound 3, which exhibited an EC50 of 1.163 nM and a CC50 >200 nM in a cell-based HCV replicon system assay. Additionally, testing for inhibition of the hERG channel showed a marked improvement over tegobuvir and the pharmacokinetic properties of compound 3 indicated that it was worthy of further investigation as a non-nucleoside inhibitor of HCV NS5B polymerase.

Design, synthesis and antifungal evaluation of novel pyrazole carboxamides with diarylamines scaffold as potent succinate dehydrogenase inhibitors

Sixteen novel pyrazole carboxamides with diarylamines scaffold were designed, synthesized and characterized in detail via 1H NMR, 13C NMR and ESI-HRMS. Preliminary bioassays showed that some of the target compounds exhibited good ant

ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE

The present invention is directed to aryl sulfamide derivatives of formula (I): or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic neuropathy, pain, and other diseases or disorders.

Synthesis and Characterization of Water-Soluble and Photolabile 10-Arylisoalloxazines: Tools for Studying the Mechanism of Action of Flavin-Type Antimalarials

Isoalloxazine derivatives such as 1a-d are promising antimalarial agents which act as inhibitors of the antioxidant enzyme glutathione reductase and possibly of other proteins.The molecular mechanism of the pharmacological effects has not been studied in detail because compounds 1a-d are poorly soluble in aqueous solutions of physiological pH.In the present study we introduce two new types of isoalloxazine derivatives with improved solubility properties.The 10-aryl-3-carboxymethylisoalloxazines 2a-d, and the isomeric 3-methyl-10-(N-methylpyridiniumyl)isoalloxazine salts 3 and 4.In addition, for the purpose of photoaffinity labeling experiments, the 10-aryl-8-azido-3-methylisoalloxazine 5 was designed.The syntheses and characterizations of these new flavins as well as an alternative synthetic approach to the known antimalarials 1a-d are described. - Keywords: Flavins/Isoalloxazines/Arylisoalloxazines/Malaria/Antimalarials/Glutathione reductase inhibitors/Photoaffinity labels

Tricyclic polyazaheterocycles for treating depression or anxiety

The invention relates to novel polycyclic polyazaheterocycles having psychopharmacological properties, especially antidepressive and anxiolytic activity, corresponding to the formula I STR1 in which R1 and R2 each represents, independently of the other, hydrogen, lower alkyl or hydroxy-lower alkyl, or together represent lower alkylene or ethyleneoxyethylene, ethyleneazaethylene or N-lower alkyl- or N-(2-hydroxy-lower alkyl)-ethyleneazaethylene, R3 represents hydrogen or a lower aliphatic hydrocarbon radical or a saturated lower cycloaliphatic hydrocarbon radical or unsubstituted or substituted phenyl, R4 and R5 represent hydrogen or lower alkyl, and Ar represents an unsubstituted or substituted benzo or pyrido radical, and to acid addition salts of compounds of the general formula I, especially the pharmaceutically acceptable acid addition salts of compounds of the general formula I, to pharmaceutical preparations containing these novel substances and to a method of treating conditions of depression or anxiety by administering them.